Marinomed Biotech AG announces results for the first quarter of 2025     Revenues for the first quarter of 2025 increased to EUR 6.5 million compared to EUR 0.7 million in Q1 2024 -steep increase of operating result to EUR 22.2 million compared to EUR -1.9 million Q1 2024 Cash and cash equivalents increased to EUR 4.5 million compared to EUR [ … ]

Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria Carragelose eye drops for the treatment of dry eyes launched under the trade name “Coldamaris protect” in Austria Eye drops complement existing Carragelose product portfolio now owned by Unither Pharmaceuticals and are important for reaching contractually agreed ear [ … ]

Marinomed focuses on growth after successful restructuring Marinomed plans to achieve an operating profit in 2025 Budesolv: innovation for the treatment of allergic rhinitis Switzerland as a stepping stone for global expansion Korneuburg, Austria, 27. March 2025 – Marinomed Biotech AG (VSE:MARI) has realigned its finances after a successful rest [ … ]

Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals All requirements for closing the deal, including shareholders’ approval and ending of the restructuring proceedings, have been met Closing is associated with an upfront payment of EUR 5 million Additionally, Marinomed and Unither entere [ … ]

 Marinomed Biotech AG: Changes to the Management Board CFO Pascal Schmidt is resigning at the end of January 2025 Gabriele Ram, former Wienerberger AG, takes over the management of the finance department on an interim basis Restructuring proceedings successfully completed, financing of the Company secured by the sale of the Carragelose business  [ … ]

Marinomed Biotech AG: Restructuring proceedings successfully completed Restructuring proceedings formally ended by resolution of the Korneuburg regional court after meeting all necessary conditions, including unanimous approval of the restructuring plan Management Board takes over administration of Company from insolvency administrator Restructu [ … ]